Recently, the Federal Trade Commission (FTC) requested comments related to the business practices of pharmacy benefit managers (PBMs) and their impact on patients. In its submission, the Alliance outlined the harms to patients that result from current industry practices related to formulary design and utilization management. As we noted in our submission, we hope that the FTC will conduct a thorough study of all aspects of the PBM industry and make recommendations for reform based on its findings.

Click here to read the letter.